he novel coronavirus disease (COVID-19), caused by SARS-CoV-2 infection, has been a serious global problem involving human health since 2019. SARS-CoV-2 is a positive-stranded RNA virus with an outer envelope surrounding the capsid constituted of the nucleocapsid protein.The envelope contains the spike glycoprotein (S), which is currently the major target of common messenger RNA (mRNA) vaccines against SARS-CoV-2. The critical routes by which SARS-CoV-2 gets into the human body are droplets and aerosol infection through the nasopharyngeal route as well as the conjunctival route. Ocular surface infections with SARS-CoV-2 are likely to allow the virus to transmit to nasopharyngeal epithelia through the lacrimal sac. 1 Therefore, pathological investigations regarding COVID-19 infection of the periocular tissues play crucial roles in better understanding how the virus spreads to the whole body. According to a 2020 review article, 2 the prevalence of ophthalmic manifestations in COVID-19 varied from 2% to 32% in different countries. Conjunctivitis is a relatively major ocular manifestation in patients with COVID-19; however, the frequency among patients is as low as other ophthalmic complications, such as retinal abnormalities, because the tear films might take part in the protection of conjunctival epithelia from virus attachments. 3 In addition, periocular COVID-19-related manifestations, including orbital cellulitis and dacryoadenitis, are extremely rare. 4,5 Angiotensin-converting enzyme 2 (ACE2) is a critical receptor by which SARS-CoV-2 preferentially adheres to the IMPORTANCE Pathological features of ophthalmic aftereffects of COVID-19 are important for new insight in treating patients.OBJECTIVE To examine the expression of SARS-CoV-2 nucleocapsid protein and angiotensin-converting enzyme 2 (ACE2) in lacrimal gland tissues of a patient with COVID-19 and a patient without COVID-19.
DESIGN, SETTING, AND PARTICIPANTSIn this retrospective case-control study, the case of a 35-year-old woman with positive test results for SARS-CoV-2 who had had lacrimal gland enlargements for 6 months was analyzed. A 43-year-old woman without COVID-19 who had idiopathic chronic bilateral dacryoadenitis served as a negative control.
MAIN OUTCOMES AND MEASURESHistopathology and immunohistochemistry with anti-SARS-CoV-2 nucleocapsid protein and ACE2 in the lacrimal glands.RESULTS Both patients were Japanese women aged 35 years (case) and 43 years (control). Histopathologic findings in the patient with COVID-19 demonstrated marked inflammatory cell infiltration, lymphoid follicles, and germinal center formation in the lacrimal gland. The inflammation was mainly made up of lymphocytes and plasma cells with several polymorphonuclear leukocytes, where the lacrimal glands were atrophic. Of note, a number of lacrimal gland ducts markedly contained eosinophilic materials in the lumens, which indicated glandular damage. Immunoreactivity for SARS-CoV-2 nucleocapsid protein was noted in the inflammatory cells around the lacrimal gland ductal epit...